Know Cancer

forgot password

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

Phase 1
18 Years
Not Enrolling
Breast Cancer, Head and Neck Cancer, Diffuse Large B-cell Lymphoma

Thank you

Trial Information

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

Inclusion Criteria:

- Patients 18 years of age or older with biopsy-proven breast cancer, head & neck
cancer or diffuse large B-cell lymphoma.

- For determination of Ki-67, S-phase, mitotic index, and sigma-2 receptor assessment,
cancer subjects must be scheduled to undergo surgical resection of the primary tumor
without intervening therapy, or be scheduled to undergo (or have already undergone)
tissue sampling as either standard of care or part of another research project prior
to any planned treatment for their cancer. For tumor sigma-2 receptors assessment,
about 0.5 g of fresh tumor tissue kept frozen on dry ice is needed, other
proliferative markers may be determined on a much smaller specimen. Thus, it is
possible that the analysis of sigma-2 receptors may not be possible in all patients,
as obtaining 0.5 g tumor specimen may not practical in all patients.

- Newly diagnosed breast cancer, head & neck cancer, or diffuse large B-cell lymphoma
subjects should have a primary lesion size ≥ 1.5 cm as determined by imaging studies
(ultrasonography, mammography, CT or MRI) or physical examination and who have not
received any treatment for their cancer.

- Able to give informed consent.

- Not currently pregnant or nursing: Female subjects must be either surgically sterile
(has had a documented bilateral oophorectomy and/or documented hysterectomy), or post
menopausal (cessation of menses for more than 1 year). If of childbearing potential,
a urine pregnancy test must be performed within the 24 hour period immediately prior
to administration of [18F]ISO-1 and determined to be negative.

Exclusion Criteria:

- Patients with other invasive malignancies, with the exception of non-melanoma skin
cancer, who had (or have) any evidence of the other cancer present within the last 5
years. Lymphoma patients who have received treatment in the past but have a new
diagnosis of diffuse large B-cell lymphoma are eligible to participate providing they
will undergo tissue sampling as specified in the inclusion criteria.

- Unable to tolerate 60-90 minutes of PET imaging.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

The primary out come is to assess the diagnostic quality of [18F]ISO-1-PET/CT images at the proposed 8 mCi dose.

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Farrokh Dehdashti, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington University in St. Louis


United States: Food and Drug Administration

Study ID:

FISO 08-1010



Start Date:

January 2009

Completion Date:

November 2011

Related Keywords:

  • Breast Cancer
  • Head and Neck Cancer
  • Diffuse Large B-Cell Lymphoma
  • Breast cancer
  • Head and Neck Cancer
  • Diffuse Large B-cell lymphoma
  • Cellular proliferation
  • Breast Neoplasms
  • Head and Neck Neoplasms
  • Hyperplasia
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse



Washington University / Barnes Jewish HospitalSaint Louis, Missouri  63110